Chemoprevention in Barrett’s Esophagus: Current Status

• Autores: Muhammad H. Zeb, Anushka Baruah, Sarah K. Kossak, Navtej S. Buttar
• Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 44, Nº. 2, 2015 (Ejemplar dedicado a: Barrett’s Esophagus), págs. 391-413
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Chemoprevention in Barrett’s esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.